Our founders — veterans of global pharmaceutical companies, contract research organizations, and investment banking — recognized a gap in the advisory landscape. Life science companies needed a partner who combined operational know-how with sophisticated deal-making capabilities and, critically, data-driven intelligence.

Tulevik was formally established with a clear mandate: become the most trusted growth advisory partner for life science companies navigating complex strategic decisions. The Estonian word for "future" was chosen deliberately — every engagement would be about building toward what's next.

While the world adapted to unprecedented disruption, we invested in building our proprietary analytics platform. By integrating clinical trial data, regulatory intelligence, and market access insights, we created a decision-support framework that gives our clients a genuine competitive edge.

We formalized partnerships with leading data providers, therapeutic-area specialists, and transaction advisors. This curated network allows us to assemble the right team for every engagement — from early-stage licensing deals to complex cross-border acquisitions.

By our third full year of operations, Tulevik had advised on engagements spanning oncology, rare disease, medical devices, and diagnostics. Our clients ranged from pre-revenue biotechs seeking licensing partners to mid-cap pharma companies evaluating bolt-on acquisitions.

Today, Tulevik continues to grow by design — not by volume. We deliberately limit the number of active engagements to ensure every client receives the strategic depth and senior attention they deserve. Our focus remains firmly on quality outcomes over quantity of deals.